Alpha-lipoic acid supplementation corrects pathological alterations in cellular models of pantothenate kinase-associated neurodegeneration with residual PANK2 expression levels.
4′-phosphopantetheinylation
Acyl carrier protein
Coenzyme A
Induced neurons
Mitochondria
PANK2
PKAN
Pantothenate kinase
Pantothenate kinase-associated neurodegeneration
α-lipoic acid
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
12 04 2023
12 04 2023
Historique:
received:
14
11
2022
accepted:
02
04
2023
medline:
14
4
2023
entrez:
12
4
2023
pubmed:
13
4
2023
Statut:
epublish
Résumé
Neurodegeneration with brain iron accumulation (NBIA) disorders are a group of neurodegenerative diseases that have in common the accumulation of iron in the basal nuclei of the brain which are essential components of the extrapyramidal system. Frequent symptoms are progressive spasticity, dystonia, muscle rigidity, neuropsychiatric symptoms, and retinal degeneration or optic nerve atrophy. One of the most prevalent subtypes of NBIA is Pantothenate kinase-associated neurodegeneration (PKAN). It is caused by pathogenic variants in the gene of pantothenate kinase 2 (PANK2) which encodes the enzyme responsible for the first reaction on the coenzyme A (CoA) biosynthesis pathway. Thus, deficient PANK2 activity induces CoA deficiency as well as low expression levels of 4'-phosphopantetheinyl proteins which are essential for mitochondrial metabolism. This study is aimed at evaluating the role of alpha-lipoic acid (α-LA) in reversing the pathological alterations in fibroblasts and induced neurons derived from PKAN patients. Iron accumulation, lipid peroxidation, transcript and protein expression levels of PANK2, mitochondrial ACP (mtACP), 4''-phosphopantetheinyl and lipoylated proteins, as well as pyruvate dehydrogenase (PDH) and Complex I activity were examined. Treatment with α-LA was able to correct all pathological alterations in responsive mutant fibroblasts with residual PANK2 enzyme expression. However, α-LA had no effect on mutant fibroblasts with truncated/incomplete protein expression. The positive effect of α-LA in particular pathogenic variants was also confirmed in induced neurons derived from mutant fibroblasts. Our results suggest that α-LA treatment can increase the expression levels of PANK2 and reverse the mutant phenotype in PANK2 responsive pathogenic variants. The existence of residual enzyme expression in some affected individuals raises the possibility of treatment using high dose of α-LA.
Sections du résumé
BACKGROUND
Neurodegeneration with brain iron accumulation (NBIA) disorders are a group of neurodegenerative diseases that have in common the accumulation of iron in the basal nuclei of the brain which are essential components of the extrapyramidal system. Frequent symptoms are progressive spasticity, dystonia, muscle rigidity, neuropsychiatric symptoms, and retinal degeneration or optic nerve atrophy. One of the most prevalent subtypes of NBIA is Pantothenate kinase-associated neurodegeneration (PKAN). It is caused by pathogenic variants in the gene of pantothenate kinase 2 (PANK2) which encodes the enzyme responsible for the first reaction on the coenzyme A (CoA) biosynthesis pathway. Thus, deficient PANK2 activity induces CoA deficiency as well as low expression levels of 4'-phosphopantetheinyl proteins which are essential for mitochondrial metabolism.
METHODS
This study is aimed at evaluating the role of alpha-lipoic acid (α-LA) in reversing the pathological alterations in fibroblasts and induced neurons derived from PKAN patients. Iron accumulation, lipid peroxidation, transcript and protein expression levels of PANK2, mitochondrial ACP (mtACP), 4''-phosphopantetheinyl and lipoylated proteins, as well as pyruvate dehydrogenase (PDH) and Complex I activity were examined.
RESULTS
Treatment with α-LA was able to correct all pathological alterations in responsive mutant fibroblasts with residual PANK2 enzyme expression. However, α-LA had no effect on mutant fibroblasts with truncated/incomplete protein expression. The positive effect of α-LA in particular pathogenic variants was also confirmed in induced neurons derived from mutant fibroblasts.
CONCLUSIONS
Our results suggest that α-LA treatment can increase the expression levels of PANK2 and reverse the mutant phenotype in PANK2 responsive pathogenic variants. The existence of residual enzyme expression in some affected individuals raises the possibility of treatment using high dose of α-LA.
Identifiants
pubmed: 37046296
doi: 10.1186/s13023-023-02687-5
pii: 10.1186/s13023-023-02687-5
pmc: PMC10091671
doi:
Substances chimiques
Iron
E1UOL152H7
pantothenate kinase
EC 2.7.1.33
Phosphotransferases (Alcohol Group Acceptor)
EC 2.7.1.-
Thioctic Acid
73Y7P0K73Y
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
80Informations de copyright
© 2023. The Author(s).
Références
Int J Mol Sci. 2019 Jan 31;20(3):
pubmed: 30708965
Curr Top Med Chem. 2015;15(5):458-83
pubmed: 25620240
EMBO Mol Med. 2019 Dec;11(12):e10488
pubmed: 31701655
Curr Protoc Hum Genet. 2013 Jan;Chapter 7:Unit7.20
pubmed: 23315928
Nutr Neurosci. 2012 Jan;15(1):1-9
pubmed: 22305647
Curr Neuropharmacol. 2013 Jan;11(1):59-79
pubmed: 23814539
Free Radic Res. 2004 Oct;38(10):1083-92
pubmed: 15512796
Redox Rep. 2005;10(1):52-60
pubmed: 15829111
Free Radic Biol Med. 2001 May 1;30(9):992-9
pubmed: 11316579
Biomaterials. 2010 May;31(15):4392-400
pubmed: 20189242
Hum Mol Genet. 2012 Sep 15;21(18):4049-59
pubmed: 22692681
Front Pharmacol. 2014 May 07;5:99
pubmed: 24847269
J Biol Chem. 2017 Aug 4;292(31):12754-12763
pubmed: 28615445
Nat Genet. 2001 Aug;28(4):345-9
pubmed: 11479594
Anal Biochem. 2004 Aug 15;331(2):370-5
pubmed: 15265744
J Med Genet. 2009 Feb;46(2):73-80
pubmed: 18981035
PLoS One. 2017 Sep 1;12(9):e0184104
pubmed: 28863176
EMBO Mol Med. 2016 Oct 4;8(10):1197-1211
pubmed: 27516453
Oxid Med Cell Longev. 2021 Jun 4;2021:6633419
pubmed: 34211631
Antioxidants (Basel). 2020 Oct 20;9(10):
pubmed: 33092139
Biochim Biophys Acta. 2015 Jul;1852(7):1257-67
pubmed: 25779083
Biochem Soc Trans. 2018 Aug 20;46(4):891-909
pubmed: 30026371
Biochim Biophys Acta Mol Basis Dis. 2020 Jun 1;1866(6):165726
pubmed: 32061767
J Vis Exp. 2018 Feb 5;(132):
pubmed: 29443113
Annu Rev Biochem. 2000;69:961-1004
pubmed: 10966480
Metab Brain Dis. 2015 Oct;30(5):1217-26
pubmed: 26084861
Int J Med Sci. 2019 Jan 1;16(1):145-155
pubmed: 30662338
Vet Clin Pathol. 2016 Dec;45(4):648-656
pubmed: 27556235
Physiol Behav. 2022 May 1;248:113727
pubmed: 35131301
Front Neurosci. 2017 Sep 28;11:530
pubmed: 29033781
Biochim Biophys Acta. 2016 Jan;1860(1 Pt A):36-45
pubmed: 26344063
Expert Opin Investig Drugs. 2002 Oct;11(10):1407-35
pubmed: 12387703
Ann N Y Acad Sci. 2004 Mar;1012:282-98
pubmed: 15105273
FEBS Lett. 1999 Jun 25;453(3):278-82
pubmed: 10405160
J Mol Model. 2012 Jul;18(7):2907-16
pubmed: 22127611
Curr Med Chem. 2004 May;11(9):1135-46
pubmed: 15134511
Hum Mol Genet. 2012 Dec 15;21(24):5294-305
pubmed: 22983956
Biofactors. 1997;6(3):321-38
pubmed: 9288403
Glia. 2010 Jan 1;58(1):55-65
pubmed: 19533605
Pharmaceuticals (Basel). 2019 Feb 09;12(1):
pubmed: 30744104
Arch Biochem Biophys. 1996 Dec 15;336(2):290-6
pubmed: 8954577
Oxid Med Cell Longev. 2010 May-Jun;3(3):206-13
pubmed: 20716945
Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):E5325-E5334
pubmed: 28634302
Inflamm Res. 2017 Nov;66(11):947-959
pubmed: 28676917
Methods Mol Biol. 2010;648:269-77
pubmed: 20700719
Diabetol Metab Syndr. 2014 Jul 28;6(1):80
pubmed: 25104975
Front Neurosci. 2018 Jul 05;12:464
pubmed: 30026686
Oncol Rep. 2017 Sep;38(3):1767-1773
pubmed: 28714034
J Biol Chem. 2009 Apr 24;284(17):11436-45
pubmed: 19221180
Mol Neurobiol. 2019 May;56(5):3638-3656
pubmed: 30173408
Biochim Biophys Acta Mol Cell Res. 2019 Dec;1866(12):118540
pubmed: 31473256
Neurobiol Dis. 2022 Apr;165:105649
pubmed: 35122944
Antioxidants (Basel). 2020 Apr 15;9(4):
pubmed: 32326494
Antioxid Redox Signal. 2010 Jan;12(1):125-69
pubmed: 19624272
Nat Prod Rep. 2014 Jan;31(1):61-108
pubmed: 24292120
Antioxidants (Basel). 2020 Oct 20;9(10):
pubmed: 33092153
Biomolecules. 2019 Aug 09;9(8):
pubmed: 31405030
Orphanet J Rare Dis. 2021 May 5;16(1):201
pubmed: 33952316
J Alzheimers Dis. 2017;57(4):1105-1121
pubmed: 28059794
Bioorg Med Chem Lett. 2010 Jul 1;20(13):3911-5
pubmed: 20605449
Neurobiol Dis. 2015 Sep;81:144-53
pubmed: 25836419
Neuroscience. 2006 Jun 19;140(1):235-46
pubmed: 16563643
Neuropathol Appl Neurobiol. 2016 Apr;42(3):220-41
pubmed: 25870938
Front Pharmacol. 2017 Dec 12;8:849
pubmed: 29311912
Cell Death Dis. 2022 Feb 25;13(2):185
pubmed: 35217637
Rare Dis. 2016 Jan 25;4(1):e1128616
pubmed: 27141409
EMBO Mol Med. 2019 Dec;11(12):e10489
pubmed: 31660701
J Biol Chem. 2009 Apr 3;284(14):9011-5
pubmed: 19028688
Orphanet J Rare Dis. 2022 Aug 9;17(1):311
pubmed: 35945593
Neurochem Res. 2022 Jul;47(7):1853-1864
pubmed: 35445914
Nat Biotechnol. 1997 Sep;15(9):871-5
pubmed: 9306402
Gene. 2010 Oct 1;465(1-2):53-60
pubmed: 20603201
Biochim Biophys Acta Mol Cell Res. 2019 May;1866(5):861-881
pubmed: 30797798
EMBO Mol Med. 2017 Aug;9(8):1117-1131
pubmed: 28646119
Curr Pharm Des. 2005;11(16):2033-52
pubmed: 15974957
Aging (Albany NY). 2013 Jan;5(1):37-50
pubmed: 23449538
Oxid Med Cell Longev. 2019 Nov 30;2019:8409329
pubmed: 31885820
N Engl J Med. 2003 Jan 2;348(1):33-40
pubmed: 12510040
PLoS Med. 2007 Mar;4(3):e76
pubmed: 17341128
Neurobiol Dis. 2015 Dec;84:78-83
pubmed: 25913028
Cell Physiol Biochem. 2008;22(5-6):769-76
pubmed: 19088458
J Biol Chem. 2018 May 18;293(20):7522-7530
pubmed: 29191830
Int J Vitam Nutr Res. 2019 Sep;89(3-4):161-167
pubmed: 30987551
Dev Med Child Neurol. 2021 Dec;63(12):1402-1409
pubmed: 34347296